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Abstract
Therapeutic angiogenesis provides a promising approach to treat ischemic cardiovascular
diseases through the delivery of proangiogenic cells and/or molecules. Outgrowth endothe-
lial cells (OECs) are vascular progenitor cells that are especially suited for therapeutic strat-
egies given their ease of noninvasive isolation from umbilical cord or adult peripheral blood
and their potent ability to enhance tissue neovascularization. These cells are recruited to
sites of vascular injury or tissue ischemia and directly incorporate within native vascular en-
dothelium to participate in neovessel formation. A better understanding of how OEC activity
may be boosted under hypoxia with external stimulation by proangiogenic molecules re-
mains a challenge to improving their therapeutic potential. While vascular endothelial
growth factor (VEGF) is widely established as a critical factor for initiating angiogenesis,
sphingosine-1-phosphate (S1P), a bioactive lysophospholipid, has recently gained great
enthusiasm as a potential mediator in neovascularization strategies. This study tests the hy-
pothesis that hypoxia and the presence of VEGF impact the angiogenic response of OECs
to S1P stimulation in vitro. We found that hypoxia altered the dynamically regulated S1P re-
ceptor 1 (S1PR1) expression on OECs in the presence of S1P (1.0 μM) and/or VEGF (1.3
nM). The combined stimuli of S1P and VEGF together promoted OEC angiogenic activity
as assessed by proliferation, wound healing, 3D sprouting, and directed migration under
both normoxia and hypoxia. Hypoxia substantially augmented the response to S1P alone,
resulting in ~6.5-fold and ~25-fold increases in sprouting and directed migration, respective-
ly. Overall, this report highlights the importance of establishing hypoxic conditions in vitro
when studying ischemia-related angiogenic strategies employing vascular progenitor cells.
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Introduction
Therapeutic angiogenesis provides a promising approach for clinical treatment of ischemic vas-
cular diseases through regenerative medicine [1–3]. Traditional strategies employ delivery of
pharmacological stimuli, recombinant growth factors, or proangiogenic cells to promote new
blood vessel formation and restore oxygenation of the hypoxic tissue [1,3–8]. Outgrowth endo-
thelial cells (OECs), also often referred to as endothelial colony forming cells (ECFCs), are vas-
cular progenitor cells that are especially suited as a cell source for treatment of ischemia [7–12].
This purely endothelial subset of endothelial progenitor cells (EPCs) may be noninvasively iso-
lated from adult peripheral or umbilical cord blood for autologous transplantation without im-
munological barriers. Further, these cells exhibit high telomerase activity, display spontaneous
vasculogenesis in vivo, are recruited to sites of vascular injury or tissue ischemia after intrave-
nous injection, and directly incorporate within native vascular endothelium to participate in
neovessel formation [4,8,12–14]. While hypoxia is known to be a critical aspect involved in
microenvironmental regulation of cellular recruitment and angiogenic sprouting [7,15–17], it
still remains unclear how OECs respond to external stimulation by soluble cues particularly
under hypoxic conditions.
Vascular endothelial growth factor (VEGF) is widely established as a potent factor for
initiating new blood vessel formation [1–3,5,18–22]. However, clinical studies involving sys-
temic administration of VEGF have had unsatisfactory results and further studies have
highlighted the presence of unstabilized and immature neovessels [1,3–6,19,23]. Therefore,
greater knowledge of the interaction between VEGF and other molecules that promote neo-
vessel stabilization in hypoxia is needed. In particular, sphingosine-1-phosphate (S1P) is a
naturally occurring, bioactive lysophospholipid that has recently attracted attention in small
molecule pharmacological strategies for therapeutic angiogenesis [24–28]. This lipid mediator
boasts essential roles in cellular trafficking and recruitment along highly regulated endoge-
nous gradients. S1P has further been touted as a complete angiogenic molecule given its
regulatory roles at both early stages of angiogenesis and later stages of neovessel stabilization
[18,23,24,29,30]. Bi-directional crosstalk between S1P and VEGF has been proposed [31–33],
but the functional nature of these stimuli on OECs in an ischemic microenvironment
remains unclear.
Few studies have explored the important relation between hypoxia and S1P and/or
VEGF signaling. S1P is carried through circulation largely in forms bound to plasma pro-
teins and is locally released by activated platelets in areas of vascular injury [27]. Overpro-
duced in hypoxia, S1P exerts pleiotropic effects on cellular processes including proliferation,
migration, cytoskeletal remodeling, and protection from apoptosis [23,27,32,34]. These
effects are largely dependent upon cell type, dose, and S1P receptor (S1PR) expression
[23,27,35,36]. Relative S1PR expression is transient and largely dependent upon the presence
of extracellular S1P and other growth factors, suggesting the importance of environmental
context on the integrated outcome of S1P signaling in a given cell type [25,30,36]. Therefore,
in order to effectively deliver S1P as a therapeutic driver of angiogenesis, it is critical to
better understand how the cellular microenvironment correlates with local S1P signaling in
human cells.
This study tests the hypothesis that reduced oxygen tension and the presence of VEGF im-
pact the angiogenic response of OECs to S1P stimulation in vitro. All assays were performed
under hypoxia (1% O2) and normoxia (ambient) and either with or without the presence of
S1P and/or VEGF. The angiogenic response of OECs was tested in vitro with different assays
that replicate key angiogenic early events including proliferation, wound healing, directed mi-
gration towards chemotactic gradients, and 3D sprouting.
Hypoxia and S1P in OEC Angiogenic Activity
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Materials and Methods
Isolation of outgrowth endothelial cells
Human umbilical cord blood (50–80 cc) was obtained from the UC Davis Umbilical Cord
Blood Collection Program (UCBCP) and was used within 12 hours of collection. Written con-
sent was not required for these studies, as all donors are kept anonymous. OECs were isolated
from female cord blood following protocols approved by the UC Davis Stem Cell Research
Oversight Committee and as previously described [4,10,37]. Blood diluted 1:1 with Hanks bal-
anced salt solution (HBSS; Sigma) was layered over an equivalent volume of Histopaque 1077
(Sigma) and centrifuged for 30 minutes at room temperature. The resultant cord blood mono-
nuclear cell (CBMNC) fraction was collected and treated with red blood cell lysis buffer
(eBioscience). The CBMNCs were then cultured on type I collagen-coated tissue culture plates
(BD Biosciences) with EGM-2MVmedium (Lonza) supplemented with 10% FBS. After 36h,
nonadherent cells were removed and the media was changed daily for adherent cells until the
first passage. Colonies of OECs appeared between 7 and 21 days of culture. Once a colony grew
to the size of a 5X field of view, the cells were detached with 0.05% Trypsin-EDTA (Life Tech-
nologies) and plated onto tissue culture treated 6-well plates (Beckton, Dickson and Company
(BD)) for continued culture in EGM-2MV. When the cells reached ~80% confluency, they
were again detached with 0.05% Trypsin-EDTA and plated onto 25-cm2 tissue culture flasks
for the first passage (P1) or 75-cm2 tissue culture flasks for subsequent passages. OECs were
used between P3 and P5 for all experiments.
Cell culture and cell expansion
EGM-2MV (Lonza) was prepared by supplementing EBM-2 with 5% fetal bovine serum (FBS),
ascorbic acid, hydrocortisone, GA-1000 antibiotic, hEGF, VEGF, hFGF-β, and IGF-1 as sup-
plied in the vendor’s kit. N media, defined as EGM-2MV without the addition of the growth
factors, was used as the negative control in all experiments. To prepare conditional medias, vas-
cular endothelial growth factor-A (165 isoform) (VEGF) (R&D Systems) and/or sphingosine-
1-phosphate (S1P) (Tocris Biosciences) were added to N media at concentrations of 50 ng/mL
and/or 1 μM, respectively. S1P was reconstituted as instructed by the manufacturer to create a
stock solution at 1 mM in sterile methanol (Sigma) and stored at -20°C [11].
Hypoxic cell culture
Cells were cultured in a hermetically sealed, modular incubator chamber (Billups-Rothenberg)
widely used for hypoxic in vitro studies [38,39]. Briefly, the chamber was flushed with a medi-
cal grade 1%-O2, 5%-CO2, 94%-N2 gas mixture (Airgas) for three minutes at 30–40 L/min to
establish hypoxia according to the manufacturer’s instructions. Humidity was reassured in the
chamber by placing a plastic petri dish containing 10 mL of sterile water on the chamber bot-
tom. The media was changed and the chamber was reflushed every 24 hrs.
Immunocytochemistry (ICC) for human S1PR1
OECs (P5) were seeded in 24-well tissue culture plates (20,000 cells/cm2) and allowed to adhere
overnight. Hypoxic plates were then transferred to the hypoxia chamber in the incubator for
continued culture. After 2 days of culture with daily changes of EGM-2MVmedium, the cells
were fixed with 4% formaldehyde (Sigma), permeabilized with 0.2% Triton X-100 (Sigma), and
blocked with 10% normal goat serum (NGS) (Life Technologies) and 1% bovine serum albu-
min (BSA; Sigma). Rabbit anti-human EDG-1 polyclonal antibody (Santa Cruz Biotech.) was
applied followed with goat anti-rabbit IgG antibody conjugated with Cy3 (Life Technologies).
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Control wells received 1.5% NGS in DPBS instead of the primary antibody. The cells were im-
aged at 20X and images were pseudocolor using ImageJ software (NIH).
Real-time quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
OECs (P4) were seeded (5,000 cells/cm2) and cultured in EGM-2MV until ~60% confluent.
The cells were then treated with conditional media and incubated under either normoxia or
hypoxia for 24h. Total RNA was extracted with RNeasy (Qiagen) and treated with DNAse I
(Qiagen). cDNA was synthesized using a high capacity cDNA reverse transcription kit (Life
Technologies) and qRT-PCR was conducted using QuantiFast SYBR Green RT-PCR Kit (Qia-
gen) and a Mastercycler RealPlex (Eppendorf). Primers for S1PR1 and β-actin (endogenous
reference) were used as previously described [40]. Gene expression relative to the appropriate
negative control (N media) in either normoxia or hypoxia was calculated via 2-ΔΔCT [11,41].
Each reaction was carried out in duplicate from two or three independent experiments.
Flow cytometry
OECs (P4) were seeded (5,000 cells/cm2) and cultured with EGM-2MV until reaching ~60%
confluency. The media was then removed and replaced with the media of interest. For hypoxic
studies, the cells were transferred to the hypoxia chamber at this time. EGM-2MV supple-
mented with 200 μMdimethyloxaloylglycine (DMOG; Sigma) was used as a hypoxia-mimicking
control as previously established [42–44]. After 24h, the cells were detached by scraping and
mixed with a micropipette to disperse any cellular aggregates. Detached cells were then sus-
pended on a rotating orbital shaker (~1 rev/sec; VWR) at 37°C for 30 minutes under either nor-
moxia or hypoxia to allow for receptor renewal at the cell surface [45]. The cell suspensions
were then collected and washed three times (500 x g for 5 min at 4°C) with cold, sterile-filtered
FACS buffer consisting of 0.5% BSA and 0.1% sodium azide (Sigma) in DPBS. The cells were
then put into microcentrifuge tubes, incubated with monoclonal antibodies against human
S1PR1 (R&D Systems) for 30 minutes at room temperature, and washed three times with FACS
buffer. PE-conjugated anti-mouse secondary antibodies were added for 30 minutes and the cells
were again washed three times with FACS buffer. Appropriate controls included unstained cells,
cells incubated with the appropriate isotype control (R&D Systems), and cells incubated with
just the secondary antibody and no primary antibody. The cells were resuspended in 0.2 mL of
FACS buffer and transferred to FACS tubes (BD Falcon) on ice. Flow cytometric analyses were
performed using a FACScan cytometer (BD) and data was analyzed using FlowJo (TreeStar Inc.,
Ashland, OR). A minimum of 10,000 events was analyzed and cells were identified as positive
by fluorescence above 95% of isotype control. The percentage of S1PR1+ cells was then calculat-
ed and normalized to controls (n = 4).
Proliferation assays
OECs (P4) were seeded at 10,000 cells/cm2 in 6-well tissue culture plates with EGM-2MV and
allowed to adhere for 5h. The growth media was then removed and the cells were starved by in-
cubation with serum-free EBM-2 for 16h. After serum deprivation, one of the four conditional
medias was added and the cells were either transferred to the hypoxia chamber or retained in
normoxia. After 3 days with daily media changes, the cells were detached with 0.05% Trypsin-
EDTA. The total number of cells was quantified with a Countess automated cell counter (Life
Technologies) and averaged per condition (n = 6). The data was then normalized to the initial
cell number based on the seeding density.
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Scratch/wound healing assays
Amodified wound-healing assay was conducted to assay cellular motility in response to the
various stimuli [46,47]. OECs (P4) were seeded (10,000 cells/cm2) and cultured in EGM-2MV
medium until reaching ~80% confluency. The cells were then starved by incubation with
serum-free EBM-2 medium for 16 hrs. A scratch was made manually down the center of the
well with a p200 micropipette tip in one swift motion as previously described [46]. One of the
four conditional medias was applied and pictures (10X) were taken at two different locations
along the scratch wound immediately after scratching [46]. The cells were incubated either
under ambient oxygen tension or within the hypoxia chamber for 12 hours, washed twice with
DPBS++, and then fixed overnight in 4% formaldehyde (Sigma) at 4°C. Pictures were then
taken at the same locations along the scratched wound that were imaged immediately after
scratching. Wound closure was quantified as the difference in scratch width between the initial
and final images at 10X using two pictures per well. The data was then normalized to the aver-
age value for the respective negative control in either normoxia or hypoxia (n = 5).
Sprouting assays
Cytodex 3 microcarrier (MC) beads (GE Healthcare Life Sciences) were hydrated overnight in
DPBS at room temperature with gentle agitation and sterilized with autoclaving. After cooling,
the sterile MC beads were mixed with 1.5 mL of OECs (~5 x 106 P4 cells) in EGM-2MVmedi-
um, transferred to a FACS tube, and incubated at 37°C with gentle agitation made by inverting
the tube 3–5 times every 20 minutes for 4h. The cell-laden MC beads were then cultured in
T25 flasks until nearly 100% confluent on a rotating orbital shaker (~1 rev/sec) at 37°C with
daily media changes. For analysis of 3D sprout formation, the cell-laden MC beads were incor-
porated within fibrin gels as previously described with minor modifications [4,48,49]. Briefly,
beads suspended in N media were combined with fibrinogen (Sigma) solution (4 mg/mL in
0.9% NaCl) supplemented with aprotinin (Sigma; ~60 μg/mL) and distributed in 24-well plates.
A second solution containing thrombin (Sigma; 2.1 U/mL in DPBS) was then added at a 4:5
ratio and the plates were incubated at 37°C for 30 minutes. Gels were then topped with one of
the four conditional medias and incubated under either normoxia or hypoxia for 1 day. The
gels were subsequently washed with DPBS and fixed overnight at 4°C in 4% formaldehyde. For
fluorescent imaging, the cells were stained with Hoescht 33342 (nuclei; Life Technologies) and
Rhodamine R18 (cell membrane; Life Technologies). The total number of beads (nT), empty
beads (nE), and sprouts (nS) was manually quantified per well. A sprout was defined as more
than one EC migrating outwards linearly while remaining anchored to the bead. The average
number of sprouts per bead in each gel, nave = nS/(nT-nE), was then calculated and normalized
to the average value for the respective negative control wells in either normoxia or hypoxia
(n = 4). Representative images of sprout formation were taken at 10X.
Alginate hydrogel formulation
Ultra-pure (UP) alginate polymer was purchased from ProNova Biomedical. MVG alginate
containing a higher G-block content (~ 60% as specified by the manufacturer) was used as the
high molecular weight (HMW; ~250 kDa) component to prepare gels. Low molecular weight
(LMW) alginate (~50 kDa) was obtained by gamma (γ)-irradiating the HMWUPMVG algi-
nate as previously described [19,48]. Both low and high MW alginate polymers were oxidized
with sodium periodate (Sigma) to an extension of 1% of the sugar residues in the polymer
[19,48]. The oxidized alginate solutions were dialysed, sterile filtered, lyophilized, and subse-
quently stored at -20°C. To prepare gels, modified alginates were reconstituted to 2% w/v in
EBM (Lonza). For S1P- and/or VEGF-loaded gels, 15 μM S1P and/or ~1.3 μg/mL VEGF was
Hypoxia and S1P in OEC Angiogenic Activity
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loaded in alginate solutions prior to addition of calcium cross-linking. A 75:25 LMW:HMW
ratio of alginate solutions was ionically crosslinked with a calcium sulfate slurry (Sigma) in a
ratio of 25:1 (40 μl of CaSO4 per 1 ml of 2% w/v alginate solution). Alginate hydrogel was dis-
pensed onto a sterile glass plate set with 1-mm spacers, sandwiched with another sterile glass
plate, and incubated for 30 minutes (at room temperature) to ensure full gelation.
Release kinetics from alginate hydrogels
Alginate hydrogels loaded with S1P were immersed in a physiological eluent buffer consisting
of EBM supplemented with 5% FBS (1 mL buffer per mL of alginate) and incubated at 37°C.
Additionally, alginate hydrogels loaded with VEGF165 were immersed in a physiological eluent
buffer consisting of DPBS++ (1 mL buffer per mL of alginate). Samples of buffer were collected
at various time points and the tubes were replenished with fresh buffer. The amounts of S1P
and VEGF released were quantified by ELISA following the manufacturers’ instructions (Eche-
lon for S1P and R&D System for VEGF165). Samples taken from blank alginate hydrogels im-
mersed in buffer were used to subtract background readings of S1P from the FBS content at
each time point (n = 4).
Directed migration assays
Amodified Transwell chemotaxis assay was used to assay 3D matrix invasion and directed mi-
gration of OECs (P4) in vitro. Transwell inserts (5 μm pores; Corning Inc.) were soaked in
EBM-2 overnight to prime the filter membranes. Bimodal 75:25 (LMW:HMW) alginate hydro-
gels loaded with S1P and/or VEGF were prepared. Blank alginate hydrogels served as the nega-
tive control. Alginate disks were punched out using a 10-mm biopsy punch (Acuderm Inc.),
placed at the bottom of each well of a 24-well plate and then covered with 0.5 mL of fibrin gel
solution. After 40–50 minutes of incubation at 37°C, 0.5 mL of N media was added on top of
the fibrin gel. A pre-incubated Transwell insert was then placed within the well, making slight
contact with the fibrin gel, and 30,000 cells were seeded into the insert in 100 μL of N media.
The plates were incubated under either normoxia or hypoxia for 48h and the inserts were then
removed using sterile tweezers. The gels were rinsed twice with DPBS++ and then fixed with
2% formaldehyde (4% formaldehyde diluted 1:1 with DPBS++) overnight at 4°C. The total
number of cells present in six representative 20X images of the gels was reported and averaged
for each condition (n = 3).
Statistical analysis
Results are shown as the mean values with standard deviations. Comparisons were assessed by
Student’s unpaired t-tests. Differences between conditions were considered significant if P<0.05.
All analyses were performed using GraphPad Prism software (GraphPad Software Inc.).
Results
OEC expression of S1PR1 is altered by microenvironment
To evaluate the presence of S1PR1 on OECs, cells were stimulated with S1P and/or VEGF both
in normoxic and hypoxic conditions. The S1PR1 expression was analyzed with immunocyto-
chemistry, real-time RT-PCR, and flow cytometry. ICC qualitatively confirmed that OECs
express S1PR1 under both normoxia and hypoxia (Fig 1A). Additionally, flow cytometry re-
vealed that the percentage of OECs that express S1PR1 on the cellular surface is increased ~1.6
fold under hypoxia as compared to normoxia (Fig 1B). This increased expression under hypox-
ia was also observed in OECs cultured with EGM-2MV containing DMOG (hypoxic control).
Hypoxia and S1P in OEC Angiogenic Activity
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While neither S1P nor VEGF augmented S1PR1 mRNA production, the combination of both
stimuli resulted in greater levels of expression under normoxia (Fig 1C). Interestingly, this
combinatory effect was not observed under hypoxia. The percentage of OECs expressing
S1PR1 was significantly increased in both normoxia and hypoxia in the presence of VEGF with
or without S1P (Fig 1D and 1E). The percentage of S1PR1+ cells was reduced in the presence
Fig 1. S1PR1 expression by OECs is dynamically altered bymicroenvironment.OEC expression of S1PR1 under normoxia and hypoxia was
qualitatively confirmed by immunocytochemistry (A). The percentage of cells expressing S1PR1 on the cell surface, as confirmed with flow cytometry, was
enhanced under hypoxia as compared to the normoxic control (B). Combined stimuli of S1P and VEGF resulted in greater S1PR1mRNA production after
24h in normoxia (C). Combined stimuli also resulted in a greater proportion of S1PR1+ OECs under both normoxia and hypoxia (D and E). Scale bars
represent 40 μm. Data are mean ± SD (n = 4) and normalized to the average untreated control values for either normoxia or hypoxia (C, E; indicated by
dashed line) accordingly. An asterisk indicates statistically significant differences (P<0.05) between conditions in normoxia or hypoxia respectively and N.S.
displays no statistically significant difference between conditions.
doi:10.1371/journal.pone.0123437.g001
Hypoxia and S1P in OEC Angiogenic Activity
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of S1P alone under normoxia, but this effect was abrogated under hypoxia. Further, percent-
ages were significantly increased by VEGF stimulation under hypoxia as compared to that
under normoxia.
The combination of S1P and VEGF results in greater proliferation
of OECs
The proliferative effect of 1 μM S1P and/or 50 ng/mL VEGF on OECs under normoxia and
hypoxia was evaluated after 3 days of stimulation. VEGF resulted in approximately 1.5-fold
and 1.3-fold increases in OEC proliferation under normoxia and hypoxia, respectively (Fig 2).
While S1P resulted in about 1.2-fold more proliferation under normoxia, this effect was abol-
ished under hypoxia. Interestingly, the combined stimuli of both S1P and VEGF led to the
greatest degree of proliferation under both oxygen tensions.
Wound healing is accelerated in response to S1P and VEGF
The ability of S1P and/or VEGF to accelerate OEC wound closure was investigated under both
normoxia and hypoxia in a scratch/wound assay (Fig 3A). Individual stimuli of either S1P or
VEGF resulted in similar degrees of accelerated wound closure versus control in normoxia (Fig
3B). VEGF also induced OEC motility under hypoxia to a similar degree as S1P, although not
statistically significant from control. S1P and VEGF together resulted in maximum rates of
wound closure under both normoxia and hypoxia, with near complete closure in normoxia
after only 12 hours.
Hypoxia augments 3D sprouting formation in response to S1P
The ability of OECs to form sprouts was used to evaluate the functional angiogenic response to
S1P and/or VEGF under both normoxia and hypoxia (Fig 4A). Interestingly, the presence of
S1P or VEGF either alone or in combination resulted in equal degrees of enhanced sprouting
formation (about 3–4 fold) under normoxia (Fig 4B). Strikingly, while VEGF resulted in only
Fig 2. The combination of S1P and VEGF induced greater OEC proliferation than either individual
stimulus under both normoxia and hypoxia. Data are mean ± SD (n = 6) and normalized to the initial cell
seeding number (indicated by dashed line). An asterisk indicates statistically significant differences (P<0.05)
between conditions in normoxia or hypoxia respectively.
doi:10.1371/journal.pone.0123437.g002
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~2-fold more sprouts/bead than control under hypoxia, co-stimulation with S1P drastically en-
hanced sprouting by ~7-fold versus control. Additionally, stimulation by S1P alone resulted in
significantly more sprouts/bead than by VEGF alone under hypoxia; this enhanced effect of
S1P was of equal magnitude to that induced by S1P and VEGF combined.
Directed migration is enhanced by S1P under hypoxia
Amodified Transwell chemotaxis assay (Fig 5A diagram) was designed and tested to evaluate
directed migration and 3D matrix invasion of OECs towards sustained gradient(s) of S1P and/
or VEGF. Quantification of S1P and VEGF release from alginate hydrogels into an aqueous
eluent buffer revealed that sustained release was achieved with roughly 80% and 40% total re-
lease, respectively, during the first 24 hours (Fig 5B). After 48h under either normoxia or hyp-
oxia, the combination of S1P and VEGF resulted in greater numbers of OECs infiltrated into
a fibrin gel that lay below the Transwell insert (Fig 5C). Interestingly, stimulation by S1P alone
resulted in as much migration as S1P and VEGF combined specifically under hypoxia, whereas
there was no effect under normoxia. In contrast, VEGF alone did not induce directed migration
versus control under either normoxia or hypoxia.
Fig 3. Combination therapy enhanced S1P-inducedmotility under both normoxia and hypoxia.OECmotility was assessed in response to 1.0 μMS1P
and/or 50 ng/mL VEGF for 12h under normoxia and hypoxia (A). S1P and VEGF combined resulted in accelerated wound closure compared to either stimuli
alone under both normoxia and hypoxia (B). Data are mean ± SD (n = 5) and normalized to the average untreated control values for either normoxia or
hypoxia (indicated by the dashed line) accordingly. An asterisk indicates statistically significant differences (P<0.05) between conditions in normoxia or
hypoxia respectively and N.S. displays no statistically significant difference between conditions.
doi:10.1371/journal.pone.0123437.g003
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Discussion
The results of this study revealed that the capacity for S1P to induce angiogenesis by OECs is
largely dependent upon oxygen tension and VEGF presence. To our knowledge, the potential
of S1P to stimulate vascular progenitor cells in hypoxia has never been tested before in vitro.
Given that reduced oxygen tension is a clinically relevant condition of tissue ischemia, we dem-
onstrated the angiogenic response of OECs to S1P (1 μM) particularly under hypoxia versus
normoxia. We established that the additional co-stimulation with VEGF (50 ng/mL) resulted
in a pronounced increase of OEC response, including proliferation, wound healing, sprouting,
and directed migration, regardless of oxygen tension. Remarkably, hypoxic culture enhanced
the response of OECs to S1P alone to a degree that was markedly as effective as S1P and VEGF
together in terms of directed migration and sprouting. Altogether, we highlight the impact of
environmental context on S1P-regulated angiogenesis by a prominent vascular progenitor cell
involved in postnatal vascularization.
We showed that OECs express S1P receptor 1 (S1PR1), a prominent S1PR involved in the
stimulatory angiogenic effects that S1P elicits in endothelial cells [11,50,51]. Previous work has
also shown that both human cord blood derived ECFCs [11] and peripheral blood derived
Fig 4. Hypoxia augmented the angiogenic response of OECs to S1P stimulation in terms of 3D sprouting formation. S1P and/or VEGF induced OEC
sprouting in a fibrin gel after 1 day of culture in normoxia and hypoxia (A). S1P alone or in combination with VEGF led to significantly more sprouts per bead
than VEGF alone under hypoxia (B). Scale bars represent 100 μm and 200 μm (DIC inlay). Data are mean ± SD (n = 4) and normalized to the average
untreated control values for either normoxia or hypoxia (indicated by the dashed line) accordingly. An asterisk indicates statistically significant differences
(P<0.05) between conditions in normoxia or hypoxia respectively and N.S. displays no statistically significant difference between conditions.
doi:10.1371/journal.pone.0123437.g004
Hypoxia and S1P in OEC Angiogenic Activity
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EPCs [51] express S1PR1 under various culture conditions under normoxia, but very little is
known about expression of S1PR1 under hypoxia. Interestingly, we observed that hypoxic con-
ditions in growth media increased the overall percentage of OECs expressing S1PR1 on the
cell surface.
OEC stimulation by exogenous VEGF with or without S1P also resulted in an enhanced por-
tion of OECs expressing S1PR1. This VEGF-induced effect was further increased ~1.6-fold
under hypoxia as compared to normoxia although the additional presence of S1P hindered this
response. This dynamic expression observed on OECs could be attributed to the fact that S1PR
expression is transient and largely dependent upon the presence of extracellular S1P and other
growth factors [25,30,36]. Accordingly, VEGF activation of sphingosine kinase-1 (SK1) pro-
motes production of S1P [32] and VEGF stimulation of bovine aortic ECs has been shown to
enhance S1PR1 expression [34]. Further, previous work has also shown that S1PR1 mRNA pro-
duction is upregulated in vivo in a hypoxia-induced mouse model of pathologic retinal angio-
genesis; this hypoxia-induced increase in S1PR1 correlated with an increase in VEGF mRNA
production as well [52]. Our studies also revealed a lower percentage of S1PR1+ OECs in the
presence of S1P stimulation alone, which accordingly may be due to receptor internalization
Fig 5. Hypoxic culture led to enhanced directedmigration towards a gradient of S1P in vitro. Amodified transwell assay was used to quantify directed
migration/3D matrix invasion of OECs towards S1P in a fibrin gel (A). Gradients of S1P and VEGF were established by sustained delivery from an alginate
hydrogel (B). While combined release of S1P and VEGF resulted in greater migration after 48h in both normoxia and hypoxia, S1P alone was equally
sufficient under hypoxia (C). Data are mean ± SD (n = 4). An asterisk indicates statistically significant differences (P<0.05) between conditions in normoxia or
hypoxia respectively and N.S. displays no statistically significant difference between conditions.
doi:10.1371/journal.pone.0123437.g005
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upon activation by S1P binding [30]. The discrepancies between our RT-PCR and flow cytome-
try based findings may be explained by the time delay between mRNA expression and protein
production/translocation to the plasma membrane [53]. However, our overall data reveals that
hypoxia alters S1PR1 expression, dynamically regulated in human OECs by the presence S1P
and/or VEGF, and promotes the importance of considering microenvironmental cues when
studying S1P for angiogenic applications.
The combination of S1P and VEGF maximally promoted early angiogenic activity assessed
via proliferation and motility (wound healing) under both normoxia and hypoxia. These two
processes are crucial for enabling vessel wall remodeling and initiating angiogenesis [18,54].
We found that 1 μM S1P was sufficient to promote OEC proliferation under normoxia in ac-
cordance with previous studies using human microvascular endothelial cells (HMVECs) [55],
umbilical vein endothelial cells (HUVECs) [56], and endothelial colony forming cells (ECFCs)
[11]. However, we further demonstrated that this proliferative response to S1P was not main-
tained under hypoxia unless VEGF (50 ng/mL) was additionally present. In contrast, S1P stim-
ulation accelerated OEC wound healing under both normoxia and hypoxia. Interestingly,
while OECs were more motile in response to VEGF under normoxia, this effect was not ob-
served under hypoxia. These overall findings, which highlight the compounded effect of dual
stimulation by S1P and VEGF under both normoxia and hypoxia in the early angiogenic activi-
ty of OECs, have not been shown before to our knowledge.
Dual stimulation was uniquely not required in order to induce functional angiogenic re-
sponses (sprouting, directed migration) of OECs to S1P stimulation although the combination
of stimuli did still have a positive effect. This finding is in contrast with a recent study, where it
was shown that combined stimulation with S1P and VEGF resulted in lower sprouting than
VEGF alone in mouse pancreatic islet-derived microvascular endothelial (MS-1) cell-covered
beads in fibrin gels after 6 days [31]. However, the study was conducted with an additional
feeder layer of human fibroblasts, which may have confounded the response to the indicated
stimuli. Interestingly, we revealed that VEGF or S1P resulted in similar levels (almost 4-fold in-
crease) of OEC sprouting in fibrin gels under normoxia and these responses were decreased or
increased, respectively, under hypoxia. Previous reports have separately shown that both
VEGF [8,19,48,49,57] and S1P [11,57] individually promote sprouting of capillary-like struc-
tures in vitro, but this is the first time to our knowledge that the responses were shown to be
oppositely altered by hypoxic conditions. Interestingly, S1P remarkably enhanced both sprout
formation (~6.5-fold) and directed migration (~25-fold) whether given alone or in conjunction
with VEGF under hypoxia. However, both S1P and VEGF were conversely required to induce
directed migration under normoxia. In contrast, previous reports have shown that 1 μM S1P
[11] and 50 ng/mL VEGF [8] each individually induce OEC chemotaxis after 4 hours under
normoxia. This discrepancy may be attributed to the fact that, in the biomaterial based method
developed within this manuscript, factors are presented as a temporally sustained gradient that
is not established in traditional chemotaxis assays. Indeed, it has been recognized that the na-
ture of the surrounding matrix greatly alters the migratory response [58,59], as observed in the
differing magnitude of the degree of motility versus directed migration that was induced by
S1P stimulation. Herein, we demonstrated overall that hypoxia positively augmented the func-
tional angiogenic responses of OECs to S1P stimulation in contrast to early angiogenic process-
es of proliferation and motility.
These studies involving the presence of VEGF and low oxygen tension confirmed the hy-
pothesized dependency of S1P-regulated angiogenesis by OECs on environmental context.
These results provide urgency towards the need for establishing hypoxic conditions in vitro
that mimic the diseased microenvironment in vivo in order to accurately glean information
about the therapeutic potential of S1P as an angiogenic mediator in future studies. Altogether,
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our results suggest the potential future for delivering S1P in a localized, spatiotemporally con-
trolled manner within ischemic tissue for local recruitment and enhanced stimulation of circu-
lating vascular progenitor cells for therapeutic angiogenesis.
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